Inappropriate Proton Pump Inhibitor Prescription in Elderly Adults: As Usual As Dangerous

1. Biessels GJ, Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: A systemic review. Lancet Neurol 2006;5:64–74. 2. Fukasawa R, Hanyu H, Sato T et al. Subgroups of Alzheimer’s disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord 2013;35:280–290. 3. Fukasawa R, Hanyu H, Shimizu S et al. Identification of diabetes-related dementia: Longitudinal perfusion SPECT and amyloid PET studies. J Neurol Sci 2015;349:45–51. 4. Fukasawa R, Hanyu H, Namioka N et al. Elevated inflammatory markers in diabetes-related dementia. Geriatr Gerontol Int 2014;14:229–231. 5. Hanyu H, Hirose D, Fukasawa R et al. Guidelines for the clinical diagnosis of diabetes mellitus-related dementia. J Am Geriatr Soc 2015;63:1721–1723. 6. Girones X, Guimera A, Cruz-Sanchez C-Z et al. N(epsilon)-carboxymethyllysin in brain aging, diabetes mellitus, and Alzheimer’s disease. Free Radic Biol Med 2004;36:1241–1247. 7. Valente T, Gella A, Fernandez-Busquets X et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 2010;37:67–76. 8. Bar KJ, Franke S, Wenda B et al. Pentosidine and N(epsilon)-(carboxymethyl)lysine in Alzheimer’s disease and vascular dementia. Neurobiol Aging 2003;24:333–338. 9. Shuvaev V, Laffont I, Serot J-M et al. Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease. Neurobiol Aging 2001;22:397–402. 10. Meli M, Perier C, Ferron C et al. Serum pentosidine as an indicator of Alzheimer’s disease. J Alzheimer Dis 2002;4:93–96.